How to Interact With Both CDRH and CDER for Drug–Device Approvals How to Interact With Both CDRH and CDER for Drug–Device Approvals Step 1: Understand the Regulatory Landscape Before initiating interactions with the FDA regarding drug-device approvals, it is imperative to thoroughly understand the regulatory landscape concerning drug and device products. The FDA regulates products under two main centers: the Center for Drug Evaluation and Research (CDER) for pharmaceuticals and the Center for Devices and Radiological Health (CDRH) for medical devices. Combination products containing both a drug component and a device component are regulated by the Office of Combination Products…

Labeling and Intended Use Alignment Between Drug and CDx Labeling and Intended Use Alignment Between Drug and CDx The development of companion diagnostics (CDx) alongside therapeutic drugs represents a rapidly evolving sector within the field of personalized medicine. Achieving regulatory compliance in the United States necessitates careful alignment between the labeling and intended use of both the drug and its corresponding diagnostic device. This step-by-step tutorial is designed to guide regulatory affairs professionals through the complex landscape of companion diagnostic regulatory consulting, ensuring a thorough understanding and adherence to relevant guidelines. Step 1: Understanding the Regulatory Framework The first step…

Analytical and Clinical Validation Requirements for CDx Devices Analytical and Clinical Validation Requirements for CDx Devices Step 1: Understanding Companion Diagnostics and Their Regulatory Framework Companion diagnostics (CDx) are in vitro diagnostic devices intended to provide information that is essential for the effective and safe use of a corresponding therapeutic product. The value of CDx lies in their ability to identify patients who are most likely to benefit from a particular treatment or to avoid potential adverse effects. Understanding the regulatory requirements surrounding CDx is vital for any organization involved in their development. In the United States, the regulatory framework…

Clinical Trial Design for Drug–CDx Combinations: Regulatory Considerations Clinical Trial Design for Drug–CDx Combinations: Regulatory Considerations In the evolving landscape of precision medicine, the integration of drug and companion diagnostics (CDx) has become crucial for optimizing patient outcomes. This article aims to provide a systematic approach for understanding and implementing the regulatory pathways and considerations involved in the clinical trial design for drug–CDx combinations, particularly focusing on the U.S. regulatory environment. Step 1: Understanding the Regulatory Framework The first step in the process of designing clinical trials for drug–CDx combinations is to familiarize yourself with the regulatory landscape set forth…

EU IVDR and Its Impact on Companion Diagnostics (IVDR Article 5) EU IVDR and Its Impact on Companion Diagnostics (IVDR Article 5) The In Vitro Diagnostic Regulation (IVDR), established by the European Union, introduces significant changes in the regulatory framework governing companion diagnostics (CDx). As professionals in the realm of regulatory affairs, it is critical to understand how these changes will affect the development, validation, and commercialization of companion diagnostics. This article serves as a step-by-step tutorial guide to navigate the complexities of IVDR Article 5 and its implications for companion diagnostics compliance in the context of US-based operations. Step…

FDA’s Codevelopment Model: IDE + IND Parallel Submissions FDA’s Codevelopment Model: IDE + IND Parallel Submissions The co-development of drug and companion diagnostics (CDx) poses unique regulatory challenges and opportunities, particularly within the framework set forth by the FDA. Utilizing the Investigational Device Exemption (IDE) and Investigational New Drug (IND) applications in parallel can streamline the development process, ensuring timely access to innovative therapies. This article will guide you through the critical steps necessary for navigating the regulatory landscape of IDE and IND parallel submissions. Step 1: Understanding the Regulatory Framework for CDx Development The first step in successfully navigating…

Regulatory Requirements for Co-Development of Drug and Diagnostic Regulatory Requirements for Co-Development of Drug and Diagnostic The confluence of pharmaceuticals and diagnostics has prompted the emergence of companion diagnostics (CDx) which harmonize drug therapies with diagnostic tests. The regulatory landscape governing the co-development of drugs and diagnostics in the United States requires a nuanced understanding of distinct regulatory pathways, documentation, and compliance with guidelines set by the FDA. This guide delineates clear, actionable steps for navigating the complex terrain of regulatory requirements for drug and diagnostic co-development. Step 1: Understanding the Rationale for Co-Development Before diving into regulatory requirements, it…

What Are Companion Diagnostics (CDx)? Role in Personalized Medicine What Are Companion Diagnostics (CDx)? Role in Personalized Medicine Advancements in personalized medicine have significantly increased the utility of companion diagnostics (CDx). These diagnostic devices contribute to the safe and effective use of therapeutic products by identifying patients who are most likely to benefit from a particular treatment. This article outlines the regulatory pathway for the development and approval of companion diagnostics in the United States, providing a step-by-step tutorial guide for professionals involved in regulatory affairs and consulting. Step 1: Understanding the Concept of Companion Diagnostics Before embarking on any…

Commercial Launch Risk Controls for Combination Products: Supply Chain and Complaint Handling in 2023 Commercial Launch Risk Controls for Combination Products: Supply Chain and Complaint Handling in 2023 The commercialization of combination products presents unique challenges and potential risks that must be addressed carefully to ensure compliance with regulatory requirements. This tutorial provides a step-by-step guide for regulatory and quality assurance teams focusing on commercial launch risk controls specific to the supply chain and complaint handling for combination products in the United States. It emphasizes practical actions, documentation expectations, and alignment with FDA regulations. Step 1: Understanding the Regulatory Framework…

Inspection Readiness for Combination Products: Audit Focus Areas and Evidence Packs in 2023 Inspection Readiness for Combination Products: Audit Focus Areas and Evidence Packs in 2023 Preparing for inspections of combination products is crucial for compliance with regulatory requirements set forth by the FDA and other international bodies. This guide provides a structured, step-by-step approach that outlines the key focus areas and documentation necessary for maintaining inspection readiness. Following these steps will help ensure that organizations are properly prepared for both internal audits and regulatory inspections. Step 1: Understanding Combination Products Regulations Combination products fall under a unique regulatory framework…